| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Director
1 company
Tom Y Lee last filed a Form 4 in August 2024, as Chief Executive Officer at PURE. From July 2015 to December 2022, the filings on record show 10 open-market purchases and 1 sale. Tom Y Lee's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 5,001,843 shares of PURE. Net of sales, the PURE filings show accumulation of 23,382,205 shares.
Shares as reported in the last Form 4 for each company; the most recent is from August 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 21, 2016 | PURE Pure Bioscience, Inc. | Director | Sell | 14,885 | $0.95 | $14,140.75 | -0.4% |